Online ISSN: 2515-8260

Keywords : Warts

Role of intralesional antigen immunotherapy in the treatment of warts

Najat Saed,Aymen Marei, Ahmad Nofal,Hagar Bessar

European Journal of Molecular & Clinical Medicine, 2021, Volume 8, Issue 3, Pages 4191-4201

Background:Warts are the most common clinical manifestation of human papillomavirus
(HPV) infection in the skin and mucous membranes, mostly found on the hands, feet, face, and
genitalia. These benign lesions have different clinical forms. There are over 200 types of this
virus and some of them have contributed in the pathophysiology of wart. Each of its types is
different in at least 10% of the sequences encoded by major capsid gene (L1). Although these
viruses have a tendency to infect some specific body parts, this disease may be manifested in
approximately all regions of the skin and mucosa. In some previous studies, it has been shown
that mumps-measles-rubella (MMR) vaccine results in regression of warts via
immunomodulation and induction of delayed (cellular) hypersensitivity reactions at the wart
tissue. This method can be used in larger populations because of vaccine availability and safety.
The varicella zoster (VZV) vaccine, which contains live attenuated virus derived from the OKA

The Efficacy Of Intralesional Bleomycin In The Treatment Of Recalcitrant Warts: An Open Therapeutic Trial In Iraq

Ahmed Yahya Abbas; Mustafa Hazim Ahmed; Hiba Hikmat Maqdasi

European Journal of Molecular & Clinical Medicine, 2020, Volume 7, Issue 9, Pages 720-728

Aesthetically, warts affect on face and hands duo to great discomfort to the patient. The common treatment methods cause pigmentary changes and scarring. Moreover, recurrence of infection. Because bleomycin is considered an anti-tumor agent, this project is considered a pioneering study in Iraq to evaluate the efficacy of bleomycin intralesional in treating intractable warts.
Patient and Methods:
A total of 23 patients with (104) rebellious warts were treated with intralesional bleomycin. The response to treatment was followed after 2 weeks, 1 month and 3 months. The follow-up method was calculated by a special recording system (no response = 0), (response = 1) and (complete recovery = 2).
Results showed at 2 weeks follow up (13.1%) of the palmoplantar, (19.4%) of the periungual and (25%) of the other sites warts improved to score 1. After 1 month the score 1 response for palmoplantar, periungual and other sites warts were (39.2%), (41.9%) and (25%) respectively, while the score 2 response for palmoplantar, periungual and other sites warts were (30.4%), (32.3%) and (75%) respectively. After three month, reaction in periungual and other sites warts is 100%, whereas in palmoplantar warts were 94.2% with a total response rate of 96.1 % according to the scoring system.
Our findings suggest that Bleomycin is significantly effective in the medication for insurgent warts. It's safe and free of side effects apart from minimal local pain with no recurrence rate of warts after bleomycin treatment.